Cohance Lifesciences promoters have fully repaid their notes, leading to the release of 57.49% of their shares from indirect encumbrances. This signifies reduced promoter-level financial risk and increased flexibility.

Cohance Lifesciences Promoters Release 57.49% Stake Post Debt Repayment

Promoters of Cohance Lifesciences Limited have successfully repaid notes worth ₹38.25 crore, resulting in the release of 219,930,170 shares, representing 57.49% of the total equity share capital, from all indirect encumbrances as of June 16, 2026.

Reader Takeaway: Debt repaid; promoters' majority stake released from pledges and covenants. Increased flexibility for promoters.

What just happened

CSCGlobal Capital Markets (Singapore) Pte. Ltd., acting as security agent, confirmed the full repayment of notes to the 2024 Lenders by Cohance Lifesciences' promoters. This repayment, as per the Notes Purchase Agreement dated May 29, 2024, led to the release of indirect encumbrances, including pledges and restrictive covenants, on 219,930,170 shares held by promoters Berhyanda Limited and Jusmiral Holdings Limited.

Why this matters

This event is significant for investors as it signals the successful resolution of debt obligations at the promoter level. The release of nearly 57.5% of the promoter shareholding from pledges and covenants reduces financial risk associated with the promoters and removes potential overhangs on their ability to deal with their stake. It provides the promoters with greater operational and financial flexibility.

The backstory

The encumbrances were indirect, relating to covenants and pledges at the promoter entity level, not directly on the company's shares. These securities were created following the Notes Purchase Agreement in May 2024.

What changes now

With the debt fully repaid, the promoters are no longer bound by the pledges and restrictive covenants tied to these notes. This allows them to have unfettered rights over their 57.49% shareholding in Cohance Lifesciences.

Risks to watch

While this is a positive development, investors should continue to monitor the company's overall financial health and any future strategic decisions the promoters may make with their now-unencumbered stake.

Peer comparison

Information on peer shareholding structures and encumbrances is not directly comparable without specific filings from other companies. However, a high percentage of promoter shareholding being free from encumbrances is generally viewed positively in the market.

Context metrics (time-bound)

• Shares Released: 219,930,170
• % of Total Share Capital Released: 57.49%
• Date of Release: June 16, 2026
• Notes Repaid Under Agreement Dated: May 29, 2024
• Total Equity Share Capital: 382,567,140 shares

What to track next

Investors should watch for any announcements regarding the strategic use of this freed-up promoter shareholding or any further corporate actions by Cohance Lifesciences.